1. A successful women entrepreneur. The chairman and managing director of biocon limited and iim bangalore Born on 23 march,1953 in banglore india Went to bishop cotton girl's high school Attended mount carmel college, bangalore, a women's college offering pre-university courses Did B.Sc. In zoology in 1973 from banglore university. Graduated in 'balting and brewing technology' from Ballort college, Melbourne, Australia Who is Kiran Mazumdar Shaw? 2. Her initial startup Returned india in 1975, didn't get appropriate jobs here, moved to UK in search of job. Met Auchincloss the owner of Biocon Biochemical limited an Ireland based company. Established Biocon(first Indian Biotech Co.) in partnership with Auchincloss on 29 Nov 1978 70% stake owned by Kiran and 30% by Auchincloss. Initial production of Biocon India was enzymes for beer, wine, paper, animal feed and detergents 3. Growth of Biocon Started with the manufacturing and export of papain, a plant enzyme and isinglass, key rpoductes for the brewing industry Established two subsidiary companies for support, namely syngene international ltd and clinigene international ltd Became india's first and the largest biotechnological company to export microbial enzymes to europe and usa Incorporated hlx biotech as a wholly owned to produce high quality drugs Started stantin business in1978 which was turning point for biocon providing nearly 78% of company's turnover. Became first indian comany to get permissin from us food and drug administration to sell statins to us 4. The Leader Emerged as # 1 biotech company in Asia and # 16 in the world in terms of revenue became the major pharmaceutical enterprise everything from insulin to antibodies Became first Indian biotech company to go public Signed Memorandum of Understanding with Deakin University, Australia to establish Deakin Research Institute in Bangalore Became the richest women in India 5. Looking ahead Movement towards the challenging venture of curing cancer Conduct research program of diabetes Strategy to expand production capacity, development of biological business and commercialization of bio- pharmaceuticals Expansion strategy not just in volume but in size of organization through mergers, acquisitions and partnerships Aimed at growing world class R&D organization by expanding R&D capabilities. 6. Current status of Biocon Biocons partner Mylan begins multicenter phase III clinical trials for insulin glargine in the United States. Biocon, through its subsidiary Biocon Research Limited (BRL), buys back GE Equity International Mauritiuss 7.69% stake in Syngene for Rs. 215.38 Crore. Subsequently, it enters into an agreement to sell 10% to Silver Leaf Oak (Mauritius) Limited, valuing Syngene at Rs. 3800 Crore. The transaction is subject to standard condition precedents including regulatory approvals in India. Syngene successfully completes USFDA pre-approval inspection of one of its manufacturing facilities. Biocon Foundation Received 'Asia Best CSR Practices Award 2014' for 'Cervical Cancer Screening Program' by the World CSR Congress. The foundation also initiated Project One, a clean drinking water initiative for rural communities in the villages its serves currently.